583 related articles for article (PubMed ID: 19802583)
1. Dengue vaccine candidates in development.
Durbin AP; Whitehead SS
Curr Top Microbiol Immunol; 2010; 338():129-43. PubMed ID: 19802583
[TBL] [Abstract][Full Text] [Related]
2. A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone.
Osorio JE; Wallace D; Stinchcomb DT
Expert Rev Vaccines; 2016; 15(4):497-508. PubMed ID: 26635182
[TBL] [Abstract][Full Text] [Related]
3. Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy.
Simmons M; Burgess T; Lynch J; Putnak R
Virology; 2010 Jan; 396(2):280-8. PubMed ID: 19913867
[TBL] [Abstract][Full Text] [Related]
4. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
[TBL] [Abstract][Full Text] [Related]
5. DENGUE VACCINES.
Thisyakorn U; Thisyakorn C
Southeast Asian J Trop Med Public Health; 2015; 46 Suppl 1():138-45. PubMed ID: 26506740
[TBL] [Abstract][Full Text] [Related]
6. Dengue virus vaccine development.
Yauch LE; Shresta S
Adv Virus Res; 2014; 88():315-72. PubMed ID: 24373316
[TBL] [Abstract][Full Text] [Related]
7. Live attenuated tetravalent dengue virus host range vaccine is immunogenic in African green monkeys following a single vaccination.
Briggs CM; Smith KM; Piper A; Huitt E; Spears CJ; Quiles M; Ribeiro M; Thomas ME; Brown DT; Hernandez R
J Virol; 2014 Jun; 88(12):6729-42. PubMed ID: 24696467
[TBL] [Abstract][Full Text] [Related]
8. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.
Guy B; Barrere B; Malinowski C; Saville M; Teyssou R; Lang J
Vaccine; 2011 Sep; 29(42):7229-41. PubMed ID: 21745521
[TBL] [Abstract][Full Text] [Related]
9. Targets and strategies for vaccine development against dengue viruses.
Wang WH; Urbina AN; Lin CY; Yang ZS; Assavalapsakul W; Thitithanyanont A; Lu PL; Chen YH; Wang SF
Biomed Pharmacother; 2021 Dec; 144():112304. PubMed ID: 34634560
[TBL] [Abstract][Full Text] [Related]
10. Development of a recombinant, chimeric tetravalent dengue vaccine candidate.
Osorio JE; Partidos CD; Wallace D; Stinchcomb DT
Vaccine; 2015 Dec; 33(50):7112-20. PubMed ID: 26585500
[TBL] [Abstract][Full Text] [Related]
11. Current progress in dengue vaccines.
Wan SW; Lin CF; Wang S; Chen YH; Yeh TM; Liu HS; Anderson R; Lin YS
J Biomed Sci; 2013 Jun; 20(1):37. PubMed ID: 23758699
[TBL] [Abstract][Full Text] [Related]
12. Using recombinant DNA technology for the development of live-attenuated dengue vaccines.
Lee HC; Butler M; Wu SC
Enzyme Microb Technol; 2012 Jul; 51(2):67-72. PubMed ID: 22664189
[TBL] [Abstract][Full Text] [Related]
13. Next-generation dengue vaccines: novel strategies currently under development.
Durbin AP; Whitehead SS
Viruses; 2011 Oct; 3(10):1800-14. PubMed ID: 22069516
[TBL] [Abstract][Full Text] [Related]
14. Dengue Vaccines: The Promise and Pitfalls of Antibody-Mediated Protection.
Martinez DR; Metz SW; Baric RS
Cell Host Microbe; 2021 Jan; 29(1):13-22. PubMed ID: 33444553
[TBL] [Abstract][Full Text] [Related]
15. Review of dengue virus and the development of a vaccine.
Murrell S; Wu SC; Butler M
Biotechnol Adv; 2011; 29(2):239-47. PubMed ID: 21146601
[TBL] [Abstract][Full Text] [Related]
16. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
[TBL] [Abstract][Full Text] [Related]
17. Live attenuated vaccine: the first clinically approved dengue vaccine?
Fink K; Shi PY
Expert Rev Vaccines; 2014 Feb; 13(2):185-8. PubMed ID: 24350687
[TBL] [Abstract][Full Text] [Related]
18. Recombinant vesicular stomatitis virus-based dengue-2 vaccine candidate induces humoral response and protects mice against lethal infection.
Lauretti F; Chattopadhyay A; de Oliveira França RF; Castro-Jorge L; Rose J; Fonseca BA
Hum Vaccin Immunother; 2016 Sep; 12(9):2327-33. PubMed ID: 27185081
[TBL] [Abstract][Full Text] [Related]
19. Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine?
Whitehead SS
Expert Rev Vaccines; 2016; 15(4):509-17. PubMed ID: 26559731
[TBL] [Abstract][Full Text] [Related]
20. Generation and preclinical evaluation of a DENV-1/2 prM+E chimeric live attenuated vaccine candidate with enhanced prM cleavage.
Keelapang P; Nitatpattana N; Suphatrakul A; Punyahathaikul S; Sriburi R; Pulmanausahakul R; Pichyangkul S; Malasit P; Yoksan S; Sittisombut N
Vaccine; 2013 Oct; 31(44):5134-40. PubMed ID: 23973247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
